Resultados da busca - John F. Kokai–Kun

  • Mostrando 1 - 16 resultados de 16
Refinar Resultados
  1. 1
    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i>

    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i> por Caroline M. Kusuma, John F. Kokai–Kun

    Publicado em 2005
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Deletion analysis of the Clostridium perfringens enterotoxin

    Deletion analysis of the Clostridium perfringens enterotoxin por John F. Kokai–Kun, Bruce A. McClane

    Publicado em 1997
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model por John F. Kokai–Kun, Tanya Chanturiya, J J Mond

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice

    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice por John F. Kokai–Kun, Tanya Chanturiya, James J. Mond

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model

    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model por John F. Kokai–Kun, S. M. Walsh, Tanya Chanturiya, James J. Mond

    Publicado em 2003
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces

    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces por Julie A. Wu, Caroline M. Kusuma, James J. Mond, John F. Kokai–Kun

    Publicado em 2003
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    COVID-19 vaccine platforms: Delivering on a promise?

    COVID-19 vaccine platforms: Delivering on a promise? por Mark Verdecia, John F. Kokai–Kun, Maura Kibbey, Sarita Acharya, Jaap Venema, Fouad Atouf

    Publicado em 2021
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  8. 8
    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens

    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens por John F. Kokai–Kun, J. Glenn Songer, John R. Czeczulin, Fei Chen, Bruce A. McClane

    Publicado em 1994
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in<i>Staphylococcus aureus</i>

    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in... por Kate Cosgrove, Graham Coutts, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Publicado em 2006
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial por John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Chenxiong Le, Heidi Whalen, Ralph W. Stevenson, Vincent J. Wacher, Joseph Sliman

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin

    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin por Simon R. Clarke, Ramlan Mohamed, Bian Li, Alexander F. Routh, John F. Kokai–Kun, James J. Mond, Andrej Tarkowski, Simon J. Foster

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i>

    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i> por Melanie R. Stapleton, Malcolm J. Horsburgh, Emma J. Hayhurst, Lynda Wright, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Publicado em 2007
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies por John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Éric Sicard, Marianne Rufiange, Richard N. Fedorak, Christian Carter, Marijke H. Adams, James Longstreth, Heidi Whalen, Joseph Sliman

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevent... por Leonard E. Weisman, Helen Thackray, Joseph A. Garcia‐Prats, Mirjana Nesin, Joseph H. Schneider, Jennifer Fretz, John F. Kokai–Kun, James J. Mond, William G. Kramer, G. Fischer

    Publicado em 2009
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection por Michael Kaleko, J. Andrew Bristol, Steven Hubert, Todd B. Parsley, Giovanni Widmer, Saul Tzipori, Poorani Subramanian, Nur A. Hasan, Perrti Koski, John F. Kokai–Kun, Joseph Sliman, Annie Jones, Sheila Connelly

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage

    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage por Simon R. Clarke, Kirsten J. Brummell, Malcolm J. Horsburgh, Philip W. McDowell, Sharifah Aminah Syed Mohamad, Melanie R. Stapleton, Jorge Luis Arroyo-Acevedo, Robert C. Read, Nicholas P. J. Day, Sharon J. Peacock, James J. Mond, John F. Kokai–Kun, Simon J. Foster

    Publicado em 2006
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: